Innoviva Inc. (INVA) |
|
14.24 -0.13 (-0.9%)
|
01-24 16:00 |
|
Open: |
14.37 |
Pre. Close: |
14.37 |
|
High:
|
14.413 |
Low:
|
14.17 |
|
Volume:
|
328,568 |
Market Cap:
|
1442M |
|
|
|
|
Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
14.444 - 14.515 |
14.515 - 14.572 |
|
Low:
|
13.972 - 14.069 |
14.069 - 14.148 |
|
Close:
|
14.104 - 14.251 |
14.251 - 14.37 |
|
Technical analysis |
as of: 2020-01-24 4:32:57 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 17.16 One year: 20.04 |
| Support: |
Support1: 14.05 Support2: 13.66 |
| Resistance: |
Resistance1: 14.69 Resistance2: 17.16 |
| Pivot: |
14.16  |
| Moving Average: |
MA(5): 14.38 MA(20): 14.16
MA(100): 12.32 MA(250): 13.26 |
| MACD: |
MACD(12,26): 0.23 Signal(9): 0.25 |
| Stochastic oscillator: |
%K(14,3): 64.40 %D(3): 70.44 |
| RSI: |
RSI(14): 57.83 |
| 52-week: |
High: 20.54 Low: 10.03 Change(%): -27.6 |
| Average Vol(K): |
3-Month: 63618 10-Days: 59251 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.INVA has closed below upper band by 41.8%. Bollinger Bands are 22.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2019-10-30
Innoviva Reports Third Quarter 2019 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the “Company”) today reported financial results for the third quarter ended September 30, 2019. Gross royalty revenues of $69.2 million from Glaxo Group Limited (“GSK”) for the third quarter of 2019 included royalties of $46.4 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $11.6 million from global net sales of ANORO® ELLIPTA® and $11.2 million from global net sales of TRELEGY® ELLIPTA®.[1] Total operating
2019-10-26
Is Innoviva, Inc. (INVA) Going To Burn These Hedge Funds ?
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
